BILL ANALYSIS �
SB 205
Page 1
Date of Hearing: August 21, 2013
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Mike Gatto, Chair
SB 205 (Corbett) - As Amended: August 19, 2013
Policy Committee: HealthVote:12-6
Business and Professions Vote: 9-3
Urgency: No State Mandated Local Program:
Yes Reimbursable: No
SUMMARY
This bill requires, by January 1, 2016, certain information on
prescription labels to be printed in at least 12-point font,
including the drug name, directions for use, the patient's name,
the dosage, and the purpose of the drug.
FISCAL EFFECT
Negligible state fiscal effect.
COMMENTS
1)Rationale . The author believes making prescription medical
container labels easier for patients to read is a simple way
to help avoid dosing or medication errors due to a patient's
inability to read the label.
2)Background . Under current law and regulation, pharmacists are
required to follow certain standards when labeling
prescription medications. Regulations adopted by the Board of
Pharmacy pursuant to SB 472 (Corbett), Chapter 470, Statutes
of 2007 require some information to be printed in at least
10-point font, including the drug name, directions for use,
the patient's name, the dosage, and the purpose of the drug.
3)Related Legislation. SB 204 (Corbett) requires pharmacists to
use translations of the directions for use developed by the
Board of Pharmacy when providing translated directions in
specified languages. For other languages, pharmacists would be
required to use certified translation services. SB 204 is
pending in the Assembly Health Committee.
SB 205
Page 2
4)Prior Legislation . SB 472 required the Board to promulgate
regulations that require, on or before January 1, 2011, a
standardized, patient-centered, prescription drug label on all
prescription medication dispensed to patients in California.
5)Opposition . The California Pharmacists Association and the
National Association of Chain Drug Stores believe changes to
prescription labeling are more appropriately handled in the
regulatory process. They indicate the existing
Patient-Centered Labeling Regulations are a product of months
of stakeholder discussion and do not believe a change is
necessary.
The Department of Consumer Affairs also opposes this bill,
stating it overrules a regulatory process by the Board of
Pharmacy. DCA also states current regulations are a product
of a lengthy examination that satisfied the needs of all
stakeholders, and does not believe there is a legitimate need
to reopen this issue.
Analysis Prepared by : Lisa Murawski / APPR. / (916) 319-2081